HOME >> MEDICINE >> NEWS
Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer

A colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical science should employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.

In today's New England Journal of Medicine, Sanford Markowitz, MD, PhD, writes an editorial accompanying research from Dr. Charles Fuchs' team at Harvard Medical School that lays out the hypothesized mechanism by which the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), also called COX-2 inhibitors, act to decrease the risk of developing colon cancer.

"The compelling evidence that chronic use of aspirin or certain NSAIDS can substantially lower the risk of colon cancer has important implications, especially because colon cancer is the second leading cause of cancer death," writes Dr. Markowitz, the Francis Wragg Ingalls Professor of Cancer Genetics at UHCMC and Case Western Reserve University School of Medicine.

In the Journal article, the Harvard researchers' findings demonstrated that two-thirds of colon cancers have high levels of expression of the COX-2 enzyme, which is blocked by aspirin. Individuals who regularly used aspirin over a course of several years demonstrated a 36% decrease in the risk of developing one of these high COX-2 expressing colon cancers. These results again demonstrated that drugs that block COX-2 can decrease the risk of colon cancer, and demonstrated that such drugs specifically target those individuals whose tumor development is encouraged by the action of the COX-2 enzyme.

Dr. Markowitz' accompanying editorial maps out those studies which will be required to determine the potential use of aspirin in prevention of colon cancer and to determine which individuals might benefit most from taking aspirin or aspirin-like drugs (NSAIDS) such as ibuprofen and Celebrex. Finally, the editorial outlines potential
'"/>

Contact: Alicia Reale
Alicia.Reale@UHhospitals.org
216-844-3825
University Hospitals of Cleveland
23-May-2007


Page: 1 2

Related medicine news :

1. Springer and the Royal Academy of Medicine of Ireland enter into publishing partnership
2. Ireland leads Europe for anti-tobacco policies while Luxembourg comes last
3. Coronary heart disease deaths in Ireland have halved in 15 years
4. Smoking ban is protecting bar workers in Ireland
5. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
6. Cancer research summaries
7. Cancer on the agenda of the Portuguese EU Council Presidency
8. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
9. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
10. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
11. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival

Post Your Comments:
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... May 22, 2015 “It’s like ... SLP, RAC-CT, CHHRP-QT, Vice President of Clinical Operations/Education ... important ‘language’ that impacts how care is coded ... in long term care reimbursement, operations and compliance ... and talent management, launches a new series of ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... 22, 2015 Memorial Day weekend is typically ... is offering some tips to help promote safe travel. ... will be 383 traffic fatalities this Memorial Day weekend. Amica ... Highway Traffic Safety Association: , , ... is wearing a seatbelt, whether they’re driving or riding along ...
(Date:5/22/2015)... 2015 Power Systems is proud to announce ... race season. Drobeck is in his second year of racing ... with the Missoula Fire Department in Missoula, MT. He entered ... 2014. During his career, he has had 15 1st Place ... top 10 finishes in all seven of his 2014 races, ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
(Date:5/22/2015)... THOUSAND OAKS, Calif. , May 22, ... today announced the Company has commenced termination ... commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN ... investigational IL-17 inhibitor, is in development for ... and axial spondyloarthritis.  The decision was based ...
(Date:5/22/2015)... 22, 2015  Effective staffing of key marketing ... and success. Research and consulting ... provide pharmaceutical and biotech marketing managers with metrics ... that are being channeled into marketing operations of ... can utilize this report to benchmark their own ...
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3
Cached News: